v3.25.3

Unaudited Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Jun. 30, 2025
Current assets:
Cash and cash equivalents	$ 32,630	$ 30,952
Accounts receivable, net	33,225	31,155
Inventories	10,100	11,434
Prepaid expenses and other current assets	5,154	5,638
Total current assets	81,109	79,179
Non-current assets:
Property and equipment, net	500	532
Operating lease right-of-use assets	1,010	1,061
Intangible assets, net	41,430	42,201
Other non-current assets	939	1,204
Total non-current assets	43,879	44,998
Total assets	124,988	124,177
Liabilities, Current [Abstract]
Accounts payable	12,342	10,601
Accrued liabilities	36,700	38,164
Revolving credit facility	14,873	9,063
Current portion of debt	1,857	1,857
Other current liabilities	221	3,379
Total current liabilities	65,993	63,064
Liabilities, Noncurrent [Abstract]
Debt, net of current portion	10,447	10,895
Derivative warrant liabilities	20,424	26,334
Other non-current liabilities	4,953	4,918
Total non-current liabilities	35,824	42,147
Commitments and contingencies (note 13)
Stockholders’ equity:
Preferred stock, par value $0.0001; 50,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, par value $0.0001; 200,000,000 shares authorized; 9,911,913 and 8,976,913 shares issued and outstanding, respectively	1	1
Additional paid-in capital	354,740	352,500
Accumulated deficit	(331,570)	(333,535)
Total stockholders’ equity	23,171	18,966
Total liabilities and stockholders’ equity	124,988	124,177
Debt Excluding Credit Facility [Member]
Liabilities, Current [Abstract]
Current portion of debt	$ 1,857	$ 1,857

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

AYTU BIOPHARMA, INC 10-Q